▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / HUMA

HUMA — Humacyte, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1818382 ·
Last close
$1.05
Market Cap
$284.47M
52W High
$1.52
52W Low
$0.55
ADV30
8,033,777
Next earnings
2026-08-10
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 495,000 -1,543,000 -28,935,000 -17,619,000 110,557,000 48,539,000 98,933,000
Dec 2025 467,000 -8,615,000 -30,836,000 -24,804,000 116,366,000 50,497,000 113,257,000
Sep 2025 753,000 493,000 -24,390,000 -17,510,000 91,509,000 19,488,000 96,260,000
Jun 2025 301,000 88,000 -29,727,000 -37,658,000 138,795,000 38,032,000 134,743,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-101,545,000
Investing CF
$-831,000
Financing CF
$38,068,000
CapEx
$-831,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.16
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-744,467,000
Inventory
$9,920,000
Receivables
$434,000
ST Investments
—
EBIT TTM
$-87,070,000
Pretax Income TTM
$-97,591,000
Interest Exp TTM
$10,521,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,016,000
EBITDA
$-105,185,000
Free Cash Flow
$-64,806,624
Enterprise Value
$252,192,160
Total Cash
$48,539,000
Total Debt
$66,501,000
Shares Out
269,638,156
Trailing EPS
$-0.63
Book Value
$0.05
ROE
-409.5%
ROA
-51.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,038,000 -108,137,000 -40,833,000 116,366,000 113,257,000 — -105,042,000
Dec 2024 0 -114,398,000 -148,701,000 137,872,000 190,541,000 — -98,122,000
Dec 2023 0 -100,047,000 -110,776,000 128,223,000 114,677,000 — -73,305,000
Dec 2022 0 -84,578,000 -11,965,000 204,302,000 87,374,000 — -71,129,000

TTM Snapshot

Revenues TTM
$2,255,000
NetIncome TTM
$-122,041,000
OpCashFlow TTM
$0
Assets (Latest)
$137,872,000
Forward EPS
$-0.26

Max Pain — expiry 2026-06-18

max pain strike: $1.00 · spot: $1.07 · call oi: 19,580 · put oi: 2,451
Expected Move to 2026-06-18: ±$0.15 (14.02%) — implied range $0.92 – $1.22 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ARMP Armata Pharmaceuticals, Inc. $278.27M $7.58 —
PALI PALISADE BIO, INC. $296.82M $1.71 —
SRZN Surrozen, Inc./DE $271.57M $23.39 —
FENC FENNEC PHARMACEUTICALS INC. $312.63M $9.00 —
LCTX Lineage Cell Therapeutics, Inc. $316.61M $1.27 —

News headlines (Yahoo Finance, 1h cache)

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
2026-06-15 16:00 · Yahoo
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
2026-06-15 12:00 · Yahoo
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
2026-06-11 01:08 · Yahoo
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
2026-06-11 00:55 · Yahoo
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses
2026-06-10 22:48 · Yahoo
Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall
2026-06-10 20:51 · Yahoo
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
2026-06-10 20:01 · Yahoo
Humacyte (HUMA) Q1 2025 Earnings Transcript
2026-06-01 14:38 · Yahoo
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis Data - Has The Bull Case Changed?
2026-05-31 08:03 · Yahoo
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
2026-05-26 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →